LL-37 is an endogenous cathelicidin with a broad spectrum of antimicrobial activity. It improves skin barrier functions, accelerates wound healing, and has a moderate anti-inflammatory effect. It is used in the treatment of acne, skin infections, and post-procedure rehabilitation.
Raw MaterialUSA
Country of OriginUAE
Purity99%
Raw MaterialUSA
Purity99%
Country of OriginUAE
Indications
Acne and skin inflammations
Slow-healing wounds
Post-laser rehabilitation
Skin infections
Therapy of skin immunity disorders
Contraindications
Autoimmune dermatoses in the acute phase.
Pregnancy, lactation.
Individual intolerance.
LL-37 is a highly concentrated form of cathelicidin designed for intensive immune and regenerative support. Its rapid bioavailability activates antimicrobial pathways, enhances barrier protection, and stabilizes inflammatory resp...
LL-37 is a highly concentrated form of cathelicidin designed for intensive immune and regenerative support. Its rapid bioavailability activates antimicrobial pathways, enhances barrier protection, and stabilizes inflammatory responses.
The peptide improves microcirculation, reduces bacterial and viral load, accelerates epithelial regeneration, and strengthens skin immune stability. LL-37 is especially effective in situations requiring strong and immediate support post-injury, during periods of reduced immune resilience, or after aesthetic and medical procedures.
LL-37 is suited for patients who need accelerated healing, reduced inflammation, or reinforcement of natural defense mechanisms. It is used in regenerative schemes, immune-support programs, post-procedure care, and comprehensive skin-healing and anti-inflammatory protocols.